PROMISE International

Sponsor
LimFlow SA (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT03321552
Collaborator
(none)
35
12
1
61.3
2.9
0

Study Details

Study Description

Brief Summary

The objective of this post-market study is to evaluate the safety and effectiveness of the LimFlow System in creating a below-the-knee arterio-venous fistula for venous arterialization in subjects with critical limb ischemia.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Percutaneous deep vein arterialization
  • Device: LimFlow System
N/A

Detailed Description

This study will investigate the safety and effectiveness of the LimFlow System for creating an arterio-venous fistula in the below-the-knee vascular system using an endovascular, minimally invasive approach for the treatment of critical limb ischemia in subjects ineligible for conventional endovascular or surgical limb salvage procedures.

Study Design

Study Type:
Interventional
Actual Enrollment :
35 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Percutaneous Deep Vein Arterialization Post-Market Study
Actual Study Start Date :
Dec 15, 2017
Anticipated Primary Completion Date :
Jul 24, 2022
Anticipated Study Completion Date :
Jan 24, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Percutaneous deep vein arterialization

Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach

Procedure: Percutaneous deep vein arterialization
Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach

Device: LimFlow System
Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach

Outcome Measures

Primary Outcome Measures

  1. Amputation-free survival [Throughout one year]

    Freedom from death or major amputation

Secondary Outcome Measures

  1. Wound healing [Throughout one year]

    Complete index wound healing as assessed by wound pictures

  2. Primary and secondary patency as assessed by duplex ultrasound [Throughout one year]

    Stent graft patency as assessed by duplex ultrasound

  3. Limb salvage: Freedom from major amputation [Throughout one year]

    Freedom from major amputation

  4. Deterioration in renal function as assessed by creatinine level [One month and six months]

    Changes in creatinine level

  5. Technical success (procedure completion) [Immediately post-procedure]

    Procedure completion and immediate morphological success with successful placement of the arterial and venous catheters in the desired location in the limb, and ability to place the stent graft

  6. Procedural success (technical success without death, major amputation, or re-intervention) [One month post-procedure]

    Combination of technical success without death, major amputation, or re-intervention

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 95 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subject must be > 21 and < 95 years of age

  • Clinical diagnosis of symptomatic critical limb ischemia, defined as Rutherford category 5 or 6

  • Assessment that no conventional surgical or endovascular treatment is possible

  • Proximally, the target in-flow artery at the cross-over point must be treatable with a 3.5 - 4.0 mm stent after pre-treatment (by visual estimate), and be <50% stenosed

  • Subject is willing and has adequate support to comply with protocol requirements, including medication regimen and follow-up visits

Exclusion Criteria:
  • Concomitant hepatic insufficiency, deep venous thrombus in target limb, uncorrected coagulation disorders, or current immunodeficiency disorder

  • Prior vein stripping surgery and/or vessel harvesting for CABG in the limb intended for study

  • Life expectancy less than 12 months

  • Patient currently taking coumarin/warfarin which, in the opinion of the attending physician, interferes with the patient's treatment

  • Any significant medical condition which, in the attending physician's opinion, may interfere with the patient's optimal treatment

  • Patient currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this treatment

  • Patient unable to give consent

  • Pregnant or breastfeeding women

  • Documented myocardial infarction or stroke within previous 90 days

  • Patients suffering from renal insufficiency (GFR value less than 30 ml/min/1.73 m²) who are not on hemodialysis

  • Patients with vasculitis and/or untreated popliteal aneurysms

  • Patients with acute limb ischemia

  • Prior peripheral arterial bypass procedure above or below the knee which could inhibit proximal inflow to the stent graft

  • Lower extremity venous disease with significant edema in the target limb that may inhibit the procedure and/or jeopardize wound healing, in the investigator's opinion

  • Known or suspected systemic or severe infection (e.g., WIfI foot Infection grade of 3)

  • Known or suspected allergies or contraindications to stainless steel, nickel, or contrast agent that cannot be adequately pre-treated, or patients who cannot receive anticoagulation or antiplatelet aggregation therapy

  • Severe heart failure, which in the opinion of the investigator may compromise subject's ability to safely undergo a percutaneous procedure (e.g., known ejection fraction of < 40%, NYHA Classification III-IV)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Universitätsklinikum Graz Graz Austria 8036
2 Universitätsklinikum Heidelberg Heidelberg Baden-Württemberg Germany 69120
3 SRH Klinikum Karlsbad-Langensteinbach Karlsbad Baden-Württemberg Germany 76307
4 Klinikum Arnsberg GmbH Arnsberg North Rhine-Westphalia Germany 59755
5 St. Franziskus-Hospital GmbH Münster North Rhine-Westphalia Germany 48145
6 Universitätsklinikum Leipzig Leipzig Saxony Germany 4103
7 Jeroen Bosch Ziekenhuis 's-Hertogenbosch Netherlands 5200 ME
8 Noordwest Ziekenhuisgroep Alkmaar Netherlands 1815 JD
9 St. Antonius Hospital Nieuwegein Netherlands 3430 EM
10 Auckland City Hospital Auckland New Zealand
11 Tan Tock Seng Hospital Singapore Singapore 308433
12 Changi General Hospital Singapore Singapore 529889

Sponsors and Collaborators

  • LimFlow SA

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
LimFlow SA
ClinicalTrials.gov Identifier:
NCT03321552
Other Study ID Numbers:
  • EU PMS Revision 4.1
First Posted:
Oct 25, 2017
Last Update Posted:
Mar 10, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by LimFlow SA
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 10, 2022